BioMarin buys Huxley for orphan drug
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical has acquired Huxley Pharmaceuticals, a virtual biotech firm with only one product, a treatment for the rare autoimmune disease Lambert Eaton myasthenic syndrome (LEMS). It will pay $15 million up front plus additional sums related to the future approval and sales of the product, amifampridine phosphate.